|
FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC): A multicenter real-life study. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; ERYTECH Pharma (Inst); Halozyme; Mylan; Rafael Pharmaceuticals; VECT-HORUS |
Speakers' Bureau - AstraZeneca; Celgene; ERYTECH Pharma; SERVIER; Shire |
Research Funding - AstraZeneca (Inst); Celgene (Inst); ERYTECH Pharma (Inst); Halozyme (Inst) |
Travel, Accommodations, Expenses - Halozyme; Ipsen; Pfizer/EMD Serono; Shire; Vect-Horus |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |